LOVENOX (enoxaparin sodium)
Lovenox is a low molecular weight heparin (LMWH) indicated for the prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal, hip replacement, or knee replacement surgeries, as well as medical patients with severely restricted mobility during acute illness. It is indicated for the inpatient treatment of acute DVT (with or without PE) and outpatient treatment of acute DVT (without PE) when administered in conjunction with warfarin. Additionally, Lovenox is used to reduce ischemic complications of unstable angina and non–Q-wave myocardial infarction (MI), and to treat acute ST-segment elevation myocardial infarction (STEMI) in patients managed medically or with subsequent PCI, when administered concurrently with aspirin.
How LOVENOX Works
Enoxaparin is an antithrombotic LMWH. Its mechanism of action is characterized by the potentiation of antithrombin III, which leads to the inhibition of coagulation factors Xa and IIa (thrombin). It possesses a higher ratio of anti-Factor Xa to anti-Factor IIa activity (approximately 3:1 to 5:1) compared to unfractionated heparin, effectively preventing the formation and propagation of fibrin clots.
Development Insights
Details
- Status
- Prescription
- First Approved
- 1993-03-29
- Revenue
- $198M (Q4-2025)
- Routes
- INJECTION, INTRAVENOUS, SUBCUTANEOUS
- Dosage Forms
- INJECTABLE
LOVENOX Approval History
What LOVENOX Treats
4 indicationsLOVENOX is approved for 4 conditions since its original approval in 1993. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Deep Vein Thrombosis
- Pulmonary Embolism
- Unstable Angina
- Myocardial Infarction
LOVENOX Boxed Warning
SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural cathet...
WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural catheters • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants • A history of traumatic or repeated epidural or spinal punctures • A history of spinal deformity or spinal surgery • Optimal timing between the administration of Lovenox and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions (5.1) and Drug Interactions (7) ] . WARNING: SPINAL/EPIDURAL HEMATOMAS See full prescribing information for complete boxed warning. Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • Use of indwelling epidural catheters • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants • A history of traumatic or repeated
LOVENOX Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in LOVENOX's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications LOVENOX treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to LOVENOX
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
16 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05735639 THRIVE | 22CX7510 ISRCTN18501431 | Ph 4 | recruiting | THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) |
| NCT04861103 | 20195544 | Ph 4 | recruiting | Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH) |
| NCT04406389 IMPACT results posted | 20-04021936 | Ph 4 | terminated | Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) |
| NCT03083704 | 16-512 | Ph 1 | completed | A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa |
| NCT02081950 results posted | ENOXA/13/1 | Ph 1 | completed | A Single-Dose Trial to Examine the Within Subject Variability of Clexane® in Healthy Adults Under Fasting Conditions |
| NCT02232802 results posted | ENOXA/14/2 | Ph 1 | completed | Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c. |
| NCT04552067 Enoxaparine | Enoxaparine | Ph 1 | completed | Enoxaparin Bioequivalence Study in Acute Coronary Syndrome Patients |
| NCT02152423 ENOXAMED | ENOXAMED | Ph 1 | completed | Enoxamed Study in the Treatment of Acute Coronary Syndromes |
| NCT01181102 results posted | DU176b-B-J302 | Ph 3 | completed | A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty |
| NCT01181167 results posted | DU176b-B-J304 | Ph 3 | completed | A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty |
| NCT01880216 | Bemiparin | Ph 3 | completed | Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT |
| NCT00679588 SAVE-ABDO | EFC6520 2007-007942-36 | Ph 3 | completed | Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery |
| NCT00916669 | 08-097 | Ph 2 | withdrawn | A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC) |
| NCT00721760 SAVE-HIP2 | EFC10343 2007-007945-11 | Ph 3 | completed | Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery |
| NCT00714597 SAVE-VEMED | EFC10572 2008-000228-13 | Ph 3 | terminated | Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility |
| NCT00697099 SAVE-HIP1 | EFC10342 2007-007944-80 | Ph 3 | completed | Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LOVENOX FDA Label Details
Indications & Usage
FDA Label (PDF)LOVENOX is indicated for the treatment of Deep Vein Thrombosis; Pulmonary Embolism; Unstable Angina; Myocardial Infarction.
WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. ...
Pro Intelligence Preview
Deep insights for LOVENOX
Revenue Insights
- • Q4-2025: $198M
- • Historical trend analysis
Patent Timeline
- • Patent expiration dates
- • Generic/biosimilar risk
Trial Analysis
- • 4 total trials
- • Stage: Mature
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment